Related Experiment Video

Updated: Jan 15, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.7K

Therapeutic targeting of prostate-specific membrane antigen could limit its potential as benchmark imaging

Melissa L Abel1, Adam Sharp2, Edwin M Posadas3

  • 1Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, MD, USA.

Nature Reviews. Urology
|October 14, 2025
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

668
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.7K

Related Experiment Videos

Last Updated: Jan 15, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.7K
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

668
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K

Articles linked to this work by shared authors, journal, and citation graph.

Comparative assessment of METastasis Reporting and Data System for Prostate Cancer versus Prostate Cancer Clinical Trials Working Group 3 Criteria in assessing treatment response in patients with metastatic castration-resistant prostate cancer.

European urology open science·2026

APUC-6 Genes as a Potential Prognostic and Predictive Biomarker in the CHAARTED Prostate Cancer Trial.

JCO precision oncology·2026

Total diffusion volume on whole-body diffusion-weighted imaging is a strong prognostic marker of disease survival in metastatic castration-resistant prostate cancer.

European radiology·2026

Durable responses to triplet immunotherapy targeting TGF-β, PD-L1, and tumor antigen, with an IL-15 receptor superagonist in mismatch repair proficient castration-resistant prostate cancer.

Journal for immunotherapy of cancer·2026

Molecular imaging and radioligand therapies in pheochromocytomas and paragangliomas.

Endocrine-related cancer·2026

PARP inhibition combined with a T-cell receptor β chain-directed antibody fusion molecule drives polyclonal antitumor immunity and tumor regression.

Journal for immunotherapy of cancer·2026

Erectile dysfunction and cardiovascular health.

Nature reviews. Urology·2026

Unconventional T cells in urological cancers: catch them if you can.

Nature reviews. Urology·2026

Integrating clinically actionable biomarkers into bladder cancer care - recommendations from the International Bladder Cancer Group.

Nature reviews. Urology·2026

The urinary microbiome, overactive bladder and bladder pain syndrome/interstitial cystitis - mechanisms, diagnostics and therapeutic opportunities.

Nature reviews. Urology·2026

Neoadjuvant intraprostatic immunotherapy for high-risk localized prostate cancer.

Nature reviews. Urology·2026

The role of CFTR in spermatogenesis and sperm quality.

Nature reviews. Urology·2026

A marine-derived meroterpenoid inhibits colorectal cancer via PI3K pathway modulation in mice.

Marine life science & technology·2026

Noncoding RNA encoded peptides in tumors from discovery to mechanism and clinical translation.

iScience·2026

SGLT2 inhibitor therapy is associated with IL-10/TGF-α/sVEGFR3 signalling and adipose tissue remodelling in advanced heart failure.

Journal of molecular and cellular cardiology plus·2026

Efficacy and safety of SCT200 in patients with recurrent or metastatic head and neck squamous cell carcinoma after platinum failure: A phase 2 study.

Cancer pathogenesis and therapy·2026

Rapamycin Attenuates Acute Pancreatitis-Induced Acinar Injury in Mice With Pancreatic Loss of Gα13.

Gastro hep advances·2026

PTC124 promotes mutation site-dependent readthrough of STK11 nonsense mutations and restores tumor suppressor function.

BBA advances·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us